Page last updated: 2024-11-12

pnu 142633f

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PNU 142633F: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10052962
MeSH IDM0354090

Synonyms (9)

Synonym
pnu-142633f
pnu 142633f
1h-2-benzopyran-6-carboxamide, 1-(2-(4-(4-(aminocarbonyl)phenyl)-1-piperazinyl)ethyl)-3,4-dihydro-n-methyl-, (1s)-, (2z)-2-butenedioate (1:1)
249765-69-3
pnu-142633 maleate
unii-vf98f3655p
vf98f3655p ,
Q27291803
(z)-but-2-enedioic acid;(1s)-1-[2-[4-(4-carbamoylphenyl)piperazin-1-yl]ethyl]-n-methyl-3,4-dihydro-1h-isochromene-6-carboxamide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events associated with PNU-142633 treatment included chest pain (two patients) and QTc prolongation (three patients)."( Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.
Azie, N; Blunt, DE; Couch, JR; Cutler, NR; Diamond, S; Fleishaker, J; Goldstein, J; Gomez-Mancilla, B; Klapper, JA; Leibowitz, MT; Smith, T; Spierings, EL, 2001
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" At higher doses (30-100 mg) the terminal half-life was relatively constant at approximately 11 hours."( Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F.
Azie, NE; Fleishaker, JC; Francom, SF; Freestone, S; Gomez-Mancilla, B; Knuth, DW; McIntosh, MJ; Pearson, LK, 1999
)
0.3
"The clinical safety and pharmacokinetic data support the study of this agent as a potential treatment for migraine attacks."( Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F.
Azie, NE; Fleishaker, JC; Francom, SF; Freestone, S; Gomez-Mancilla, B; Knuth, DW; McIntosh, MJ; Pearson, LK, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's7 (87.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]